CD4 and tuberculosis: After data extraction, 23 studies were excluded, including those comparing the same core agent/NRTI combinations (n = 8) [29–37], special HIV populations (patients coinfected with tuberculosis or with specific CD4+ cell requirements other than < 200 cells/μL; n = 8) [38–49], conducted in subgroup of interest (CD4+ < 200 cells/μL) but not reporting outcomes of interest (n = 2) [50, 51], and outcomes not reported at Week 48 (n = 5) [52–56].